• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/5/21 6:10:51 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    SC 13G 1 tak1272112sc13g.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

      

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. n/a)*

     

     

    Takeda Pharmaceutical Company Limited
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    874060205
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒       Rule 13d-1(b)

     

    ☐       Rule 13d-1(c)

     

    ☐       Rule 13d-1(d)

     

    _____________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 6 
     

     

    CUSIP No. 874060205                 13G  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Holdings, Inc.

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)    ☐
       

    (b)    ☐

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    85,301,634

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    94,034,034

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    94,034,034

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.0%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

     

     Page 2 of 6 
     

     

     Item 1(a). Name of Issuer:

     

    Takeda Pharmaceutical Company Limited

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan

     

    Item 2(a). Name of Person Filing:

     

    Sumitomo Mitsui Trust Holdings, Inc.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    Item 2(c). Citizenship:

     

    Japan

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock

     

    Item 2(e). CUSIP Number:

     

    874060205

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) ☐  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) ☐  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ☐  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☒  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☒  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ☐  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

     Page 3 of 6 
     

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    (a)   Amount beneficially owned: 94,034,034
         
    (b)   Percent of class: 6.0%
         
    (c)   Number of shares as to which such person has:
         
    (i)   Sole power to vote or to direct the vote: 0
         
    (ii)   Shared power to vote or to direct the vote: 85,301,634
         
    (iii)   Sole power to dispose or to direct the disposition of: 0
         
    (iv)   Shared power to dispose or to direct the disposition of: 94,034,034

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 4 of 6 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 5, 2021

     

      Sumitomo Mitsui Trust Holdings, Inc.
      (Company)
       
      /s/ Tomokazu Kusumi
     

    (Signature)

     

    Tomokazu Kusumi / Senior Manager of Risk
    Management Dept 

      (Name/Title)

     

     Page 5 of 6 
     

     

    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, portions of the securities being reported on by Sumitomo Mitsui Trust Holdings, Inc. as a parent holding company are owned, or may be deemed to be beneficially owned, by its subsidiaries: each of (a) Sumitomo Mitsui Trust Asset Management Co., Ltd. and (b) Nikko Asset Management Co., Ltd. is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E) and as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

    Page 6 of 6

     

     

     

    Get the next $TAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/8/2026Mkt Perform → Outperform
    Bernstein
    1/13/2026Overweight
    Morgan Stanley
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    SEC Filings

    View All

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    6/1/26 6:06:12 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    5/26/26 6:12:38 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

    6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

    5/26/26 6:11:43 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Takeda Pharma upgraded by Bernstein

    Bernstein upgraded Takeda Pharma from Mkt Perform to Outperform

    4/8/26 9:38:13 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Takeda Pharma

    Morgan Stanley resumed coverage of Takeda Pharma with a rating of Overweight

    1/13/26 8:31:07 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Pharma upgraded by Morgan Stanley

    Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

    4/2/25 8:46:19 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

    FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration   Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch

    5/13/26 2:38:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

    TORONTO, May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.1 Coverage is subject to specific criteria.2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes."We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short

    5/5/26 8:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

    Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda ((TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrate

    5/4/26 8:00:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Smoter Jennifer Marie

    3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    5/5/26 6:31:45 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    4/28/26 6:08:54 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)

    4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)

    4/28/26 6:07:30 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Leadership Updates

    Live Leadership Updates

    View All

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

    − Rhonda Pacheco to Succeed Julie Kim, Who Was Appointed to Be Takeda's Next CEO Takeda ((TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco's appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division. This press r

    9/11/25 8:45:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Financials

    Live finance-specific insights

    View All

    Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

    FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration   Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch

    5/13/26 2:38:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

    About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven

    3/28/26 3:00:00 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

    Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment   Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The comp

    1/29/26 1:37:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/6/24 9:36:34 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/5/24 6:24:58 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

    SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

    2/7/23 2:10:49 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care